JP Patent

JP5921439B2 — 結晶形態ｉｉの７−［３，５−ジヒドロキシ−２−（３−ヒドロキシ−５−フェニル−ペント−１−エニル）−シクロペンチル］−ｎ−エチル−ヘプト−５−エナミド（ビマトプロスト）、その調製方法、およびその使用方法

Assigned to Allergan Inc · Expires 2016-05-24 · 10y expired

What this patent protects

Patent listed against Lumigan.

Drugs covered by this patent

Patent Metadata

Patent number
JP5921439B2
Jurisdiction
JP
Classification
—
Expires
2016-05-24
Drug substance claim
No
Drug product claim
No
Assignee
Allergan Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.